IBDEI1XR ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,32834,1,3,0)
 ;;=3^Family Hx of Glaucoma
 ;;^UTILITY(U,$J,358.3,32834,1,4,0)
 ;;=4^Z83.511
 ;;^UTILITY(U,$J,358.3,32834,2)
 ;;=^5063382
 ;;^UTILITY(U,$J,358.3,32835,0)
 ;;=Z83.518^^128^1636^12
 ;;^UTILITY(U,$J,358.3,32835,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32835,1,3,0)
 ;;=3^Family Hx of Eye Disorder
 ;;^UTILITY(U,$J,358.3,32835,1,4,0)
 ;;=4^Z83.518
 ;;^UTILITY(U,$J,358.3,32835,2)
 ;;=^5063383
 ;;^UTILITY(U,$J,358.3,32836,0)
 ;;=Z83.52^^128^1636^9
 ;;^UTILITY(U,$J,358.3,32836,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32836,1,3,0)
 ;;=3^Family Hx of Ear Disorder
 ;;^UTILITY(U,$J,358.3,32836,1,4,0)
 ;;=4^Z83.52
 ;;^UTILITY(U,$J,358.3,32836,2)
 ;;=^5063384
 ;;^UTILITY(U,$J,358.3,32837,0)
 ;;=Z83.71^^128^1636^4
 ;;^UTILITY(U,$J,358.3,32837,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32837,1,3,0)
 ;;=3^Family Hx of Colonic Polyps
 ;;^UTILITY(U,$J,358.3,32837,1,4,0)
 ;;=4^Z83.71
 ;;^UTILITY(U,$J,358.3,32837,2)
 ;;=^5063386
 ;;^UTILITY(U,$J,358.3,32838,0)
 ;;=Z83.79^^128^1636^8
 ;;^UTILITY(U,$J,358.3,32838,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32838,1,3,0)
 ;;=3^Family Hx of Digestive System Diseases
 ;;^UTILITY(U,$J,358.3,32838,1,4,0)
 ;;=4^Z83.79
 ;;^UTILITY(U,$J,358.3,32838,2)
 ;;=^5063387
 ;;^UTILITY(U,$J,358.3,32839,0)
 ;;=Z79.1^^128^1637^3
 ;;^UTILITY(U,$J,358.3,32839,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32839,1,3,0)
 ;;=3^Long Term Current Use of NSAID
 ;;^UTILITY(U,$J,358.3,32839,1,4,0)
 ;;=4^Z79.1
 ;;^UTILITY(U,$J,358.3,32839,2)
 ;;=^5063332
 ;;^UTILITY(U,$J,358.3,32840,0)
 ;;=Z79.52^^128^1637^5
 ;;^UTILITY(U,$J,358.3,32840,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32840,1,3,0)
 ;;=3^Long Term Current Use of Systemic Steroids
 ;;^UTILITY(U,$J,358.3,32840,1,4,0)
 ;;=4^Z79.52
 ;;^UTILITY(U,$J,358.3,32840,2)
 ;;=^5063336
 ;;^UTILITY(U,$J,358.3,32841,0)
 ;;=Z79.82^^128^1637^2
 ;;^UTILITY(U,$J,358.3,32841,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32841,1,3,0)
 ;;=3^Long Term Current Use of Aspirin
 ;;^UTILITY(U,$J,358.3,32841,1,4,0)
 ;;=4^Z79.82
 ;;^UTILITY(U,$J,358.3,32841,2)
 ;;=^5063340
 ;;^UTILITY(U,$J,358.3,32842,0)
 ;;=Z79.810^^128^1637^4
 ;;^UTILITY(U,$J,358.3,32842,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32842,1,3,0)
 ;;=3^Long Term Current Use of SERMs
 ;;^UTILITY(U,$J,358.3,32842,1,4,0)
 ;;=4^Z79.810
 ;;^UTILITY(U,$J,358.3,32842,2)
 ;;=^5063337
 ;;^UTILITY(U,$J,358.3,32843,0)
 ;;=Z79.811^^128^1637^1
 ;;^UTILITY(U,$J,358.3,32843,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32843,1,3,0)
 ;;=3^Long Term Current Use of Aromatase Inhibitors
 ;;^UTILITY(U,$J,358.3,32843,1,4,0)
 ;;=4^Z79.811
 ;;^UTILITY(U,$J,358.3,32843,2)
 ;;=^5063338
 ;;^UTILITY(U,$J,358.3,32844,0)
 ;;=E78.5^^128^1638^5
 ;;^UTILITY(U,$J,358.3,32844,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32844,1,3,0)
 ;;=3^Hyperlipidemia,Unspec
 ;;^UTILITY(U,$J,358.3,32844,1,4,0)
 ;;=4^E78.5
 ;;^UTILITY(U,$J,358.3,32844,2)
 ;;=^5002969
 ;;^UTILITY(U,$J,358.3,32845,0)
 ;;=E66.9^^128^1638^8
 ;;^UTILITY(U,$J,358.3,32845,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32845,1,3,0)
 ;;=3^Obesity,Unspec
 ;;^UTILITY(U,$J,358.3,32845,1,4,0)
 ;;=4^E66.9
 ;;^UTILITY(U,$J,358.3,32845,2)
 ;;=^5002832
 ;;^UTILITY(U,$J,358.3,32846,0)
 ;;=E66.01^^128^1638^7
 ;;^UTILITY(U,$J,358.3,32846,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32846,1,3,0)
 ;;=3^Morbid Obesity
 ;;^UTILITY(U,$J,358.3,32846,1,4,0)
 ;;=4^E66.01
 ;;^UTILITY(U,$J,358.3,32846,2)
 ;;=^5002826
 ;;^UTILITY(U,$J,358.3,32847,0)
 ;;=E66.3^^128^1638^10
 ;;^UTILITY(U,$J,358.3,32847,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32847,1,3,0)
 ;;=3^Overweight
